ClinicalTrials.gg
CompletedNCT01687491AXAUpdated Nov 3, 2015

Comparison of Anti-Xa Activity of ENOXA ® Versus LOVENOX ® in Acute Coronary Syndrome

A Phase 4 interventional study of ENOXA® and LOVENOX® in Acute Coronary Syndrome and Factor X, sponsored by Les Laboratoires des Médicaments Stériles. Completed at 1 site in Tunisia. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-11-03.

Sponsored by Les Laboratoires des Médicaments Stériles · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
179
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Acute Coronary Syndrome with a site in Tunisia — none open to participants now, none under way, none of them phase 3. Acute Coronary Syndrome · Tunisia.

Enrollment
9th of 12
179 · median 966
Started
2012
with 1 other
Phase 4
Only one
of the 13
Registered
8th of 13
by date
Lead sponsor
1 of 13
Les Laboratoires des Médicaments Stériles

Among the 13 studies in Acute Coronary Syndrome with a site in Tunisia, this one is the 9th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2012, is the only one in phase 4, and was the 8th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

None of the 13 studies in Acute Coronary Syndrome with a site in Tunisia is open now. The open studies under Acute Coronary Syndrome, anywhere →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Acute Coronary Syndrome with a site in Tunisia as a file.
02

Study summary

This study is a clinical trial monocentric, open, randomized ENOXA ® versus LOVENOX ®, conducted on two parallel groups of patients admitted in emergency for acute coronary syndrome.

Read the detailed description

The patients included in this study with an acute coronary Syndrome be admitted to the emergency room and receive treatment with enoxaparin. Low molecular weight heparin (LMWH) treatment in this indication is usually spread over a week. The experience of the study intends to focus only on the first injection administered in selected patients.

Two assays are carried out, including an assessment of the anti-Xa activity initially before injection of enoxaparin, and 4 hours after administration of the first syringe.

Clinical monitoring is intrahospital from the date of hospitalization of patients included until emergency exit (transfer to another service, or return home)

Tolerance assessment (clinical and biological) is performed during follow-up.

03

Conditions studied

  • Acute Coronary Syndrome
  • Factor X

Keywords

  • Enoxaparin
  • Acute Coronary Syndrome
  • Factor X
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female over the age of 20 years
  • acute coronary syndrome
  • Admission to the emergency department

Exclusion criteria

Exclusion Criteria:

  • Patient participating in another study
  • Pregnant or lactating or of not using medically accepted method of
  • Taking an anticoagulant in the last three months
  • Patient with known haemostatic disorder
  • absolute and / or relative to the use of enoxaparin
  • Nobody wishing to participate in this study or not having the ability to understand its objectives
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
179 participants (actual)

Study arms

  • Active comparator
    Enoxa

    ENOXA® Anti-Xa/kg 100 IU by subcutaneous injection every 12 hours

    Drug: ENOXA®

  • Active comparator
    Lovenox

    LOVENOX® Anti-Xa/kg 100 IU by subcutaneous injection every 12 hours

    Drug: LOVENOX®

Interventions

  • DrugENOXA®

    enoxaparine 100 UI/Kg subcutaneous injection

  • enoxaparine 100 UI/Kg subcutaneous injection

06

What researchers measure

Primary outcomes

  1. anti-Xa activity

    assay of anti-Xa activity 4 hours after the first injection énoxparine

    Time frame: 4 hours

Secondary outcomes

  1. adverse events

    Tolerance is assessed by the occurrence of adverse events and / or serious adverse events

    Time frame: participants will be followed for the duration of hospital stay, an expected average of 7 days

07

Study locations

1 site
  • Departement of Emergency
    Monastir, 5000, Tunisia
08

References and documents

Publications

  • Boubaker H MD, Grissa MH MD, Sassi M MD, Chakroun T MD, Beltaief K MD, et al. (2015) Generic and Branded Enoxaparin Bioequivalence: A Clinical and Experimental Study. J Bioequiv Availab 7: 225-228. doi:10.4172/jbb.1000244
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of May 2013 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2012
First posted
Sep 19, 2012
Start
Jul 2012
Primary completionActual
May 2013
CompletionActual
Oct 2014
Last update
Nov 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01687491
Lead sponsor
Les Laboratoires des Médicaments Stériles
Collaborators
University Hospital Fattouma Bourguiba
Responsible party
Sponsor
First posted
Sep 19, 2012
Start date
Jul 2012
Primary completion
May 2013
Completion
Oct 2014
Last update
Nov 3, 2015

Study contacts

Semir Nouira, PHD
study chair · Fattouma Bourguiba Hospital, Monastir
Mohsen Hassine
principal investigator · Fattouma Bourguiba, Monastir

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enoxaparin sodium

Start the discussion